Skip to main content

Advertisement

Log in

Health-Related Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial

  • Healthcare Policy and Outcomes
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

A recent prospective randomized trial demonstrated that prophylactic pasireotide reduces the incidence of pancreatic complications (PC) after resection. This secondary analysis aimed to describe quality of life (QoL) before and after resection, to characterize the impact of PC on QoL, and to assess whether pasireotide improves QoL.

Methods

A randomized, double-blind, placebo-controlled trial of preoperative pasireotide in patients undergoing pancreatectomy was conducted. Participants completed the European Organization for Research and Treatment of Cancer (EORTC) C30 and PAN26 modules preoperatively and on postoperative days 14 and 60. Scores were compared using t tests. The percentage of patients with clinically important worsening (a decline ≥0.5 times the baseline standard deviation) was reported.

Results

All questionnaires were completed by 87 % (260/300) of the patients. No major differences were observed between the pasireotide and placebo groups. Therefore, the data were pooled for further analyses. A significant worsening of function at 14 days was detected on all the PAN26 and C30 function scales except hepatic and emotional functioning (EF), and on all the C30 symptom scales. More than 75 % of the patients experienced clinically important worsening of fatigue, pain, and role functioning. Most effects persisted at 60 days, with the 60-day EF significantly better than at baseline (p = 0.03). PC were associated with worse outcomes on most function scales.

Conclusions

During the 14 days after resection, patients can be expected to have a significant decline in QoL. Many symptoms abate by 60 days, and EF improves. PC were associated with impaired QoL in several domains. Although pasireotide effectively reduced PC, its effect did not appear to translate to improved QoL in this sample of 300 patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg. 1995;221:721–31; discussion 721–31

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg. 1996;83:625–31.

    Article  CAS  PubMed  Google Scholar 

  3. Numico G, Longo V, Courthod G, Silvestris N. Cancer survivorship: long-term side effects of anticancer treatments of gastrointestinal cancer. Curr Opin Oncol. 2015;27:351–7.

    Article  CAS  PubMed  Google Scholar 

  4. Spalding NJ. Reducing anxiety by preoperative education: make the future familiar. Occup Ther Int. 2003;10:278–93.

    Article  PubMed  Google Scholar 

  5. Wilson CJ, Mitchelson AJ, Tzeng TH, et al. Caring for the surgically anxious patient: a review of the interventions and a guide to optimizing surgical outcomes. Am J Surg. 2015. doi: 10.1016/j.amjsurg.2015.03.023

    PubMed Central  Google Scholar 

  6. Fitzsimmons D, Johnson CD, George S, et al. Development of a disease-specific quality-of-life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer Oxford Engl 1990. 1999;35:939–41.

    CAS  Google Scholar 

  7. EORTC. Modules in Development and Available for Use. http://groups.eortc.be/qol/modules-development-and-available-use. Accessed 1 June 2015

  8. Keck T, Wellner UF, Bahra M, et al. Pancreatogastrostomy versus pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): perioperative and long-term results of a multicenter randomized controlled trial. Ann Surg. 2015. doi: 10.1097/SLA.0000000000001240

    Google Scholar 

  9. Moningi S, Walker AJ, Hsu CC, et al. Correlation of clinical stage and performance status with quality of life in patients seen in a pancreas multidisciplinary clinic. J Oncol Pract/Am Soc Clin Oncol. 2015;11:e216–21.

    Article  Google Scholar 

  10. Allen PJ, Gönen M, Brennan MF, et al. Pasireotide for postoperative pancreatic fistula. N Engl J Med. 2014;370:2014–22.

    Article  PubMed  Google Scholar 

  11. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: EORTC Publications; 2001.

    Google Scholar 

  12. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–92.

    PubMed  Google Scholar 

  13. Crippa S, Dominguez I, Rodriguez JR, et al. Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg. 2008;12:783–93; discussion 793–94

    Article  PubMed  PubMed Central  Google Scholar 

  14. Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB, Obertop H, de Haes JC, Gouma DJ. Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg. 2005;92:471–7

    Article  CAS  PubMed  Google Scholar 

  15. Schniewind B, Bestmann B, Henne-Bruns D, Faendrich F, Kremer B, Kuechler T. Quality of life after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head. Br J Surg. 2006;93:1099–107.

    Article  CAS  PubMed  Google Scholar 

  16. McNulty J, Khera N. Financial hardship: an unwanted consequence of cancer treatment. Curr Hematol Malig Rep. 2015. doi: 10.1007/s11899-015-0266-1

    PubMed  Google Scholar 

  17. Shaw CM, O’Hanlon DM, McEntee GP. Long-term quality of life following pancreaticoduodenectomy. Hepatogastroenterology. 2005;52:927–32.

    PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by Cancer Center core grant P30 CA008748. The core grant provides funding to institutional cores such as Biostatistics, which was used in this study. The research was funded by Novartis.

Disclosure

Dr Peter J. Allen has worked in a consulting/advisory role for Sanofi and received research funding from Novartis.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anne A. Eaton MS.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 1 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eaton, A.A., Gonen, M., Karanicolas, P. et al. Health-Related Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial. Ann Surg Oncol 23, 2137–2145 (2016). https://doi.org/10.1245/s10434-015-5077-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-5077-z

Keywords

Navigation